Pharmaceutical composition and a method for its manufacture

A storage stable pharmaceutical composition comprising at least one active pharmaceutical ingredient selected from peptides of the general formula 1 [SEQ ID NO:

• 1-144]
• H-XDL-XDL1-XDL2-L-Lys-L-Leu-XDL3-L-Thr-R2 (1),
• wherein:
• H—hydrogen,
• XDL—the absence of an amino acid or L-Tyr,
• XDL1—one of the amino acids:
• L-Leu, L-Ala or D-Ala,
• XDL2—one of the amino acids:
• L-His, D-His, L-Ala or D-Ala,
• XDL3—one of the amino acids:
• L-Gln, L-Ala or D-Ala;
• R2—OMe, or NHz;
• or
• peptides of the general formula 2 [SEQ ID NO:
• 145-288]
• H-D-Thr-XDL4-D-Leu-D-Lys-XDL5-XDL6-XDL7-R2 (2),
• wherein:
• H—hydrogen,
• XDL4—one of the amino acids:
• D-Gln, D-Ala or L-Ala,
• XDL5—one of the amino acids:
• D-His, L-His, D-Ala or L-Ala,
• XDL6—one of the amino acids:
• D-Leu, D-Ala or L-Ala,
• XDL7—the absence of an amino acid or D-Tyr,
• R2—OMe, or NH2;
• or, their derivatives, analogs or pharmaceutically acceptable salts, or co-crystals of these peptides, their derivatives or analogues;
• and a pharmaceutically acceptable carrier,
• wherein the composition retains at least 80% of the potency of active pharmaceutical ingredient in the pharmaceutical composition after storage for at least four months at room temperature.